Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Hualan Group
301027
5
Hangzhou SDIC Microelectronics Inc.
688130
CN Stock MarketDetailed Quotes
300485 Beijing Science Sun Pharmaceutical
- 7.64
- -0.21-2.68%
Trading Apr 11 11:26 CST
3.68BMarket Cap-53.43P/E (TTM)
7.93High7.60Low127.95KlotVolume7.70Open7.85Pre Close99.26MTurnover4.67%Turnover RatioLossP/E (Static)481.67MShares9.4552wk High1.10P/B2.09BFloat Cap5.7352wk Low9.42Limit Up273.82MShs Float43.34Historical High6.28Limit Down4.20%Amplitude5.73Historical Low0.02Dividend TTM7.76Avg Price77.40KlotAsk0.29%Div YieldTTM100Lot Size48.08KlotBid
Beijing Science Sun Pharmaceutical Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Current assets | ||||||||||
| Money funds | -37.37%75.26M | -46.27%108.35M | -67.26%71.2M | -38.48%126.24M | -46.88%120.16M | 68.65%201.67M | 91.18%217.46M | -10.64%205.2M | 40.03%226.21M | -69.72%119.58M |
| Transactional financial assets | 42.05%1.5B | 59.65%1.42B | 33.61%1.14B | 19.56%1.1B | 17.65%1.05B | -23.15%890.08M | -24.97%854.63M | -12.13%921.14M | -21.08%895.39M | 35.13%1.16B |
| Notes receivable and accounts receivable | -3.17%50.75M | -17.46%56.19M | -16.70%56.59M | -33.41%52.91M | -38.16%52.42M | -30.52%68.08M | -21.98%67.93M | -11.30%79.46M | -11.88%84.76M | -4.44%97.98M |
| -Notes receivable | -37.19%3.43M | -25.30%4.62M | -41.01%3.94M | -57.00%4.4M | -37.76%5.46M | -27.89%6.19M | 27.78%6.68M | 115.14%10.23M | 75.48%8.78M | 1,048.58%8.58M |
| -Accounts receivable | 0.79%47.32M | -16.67%51.57M | -14.05%52.65M | -29.93%48.52M | -38.21%46.95M | -30.77%61.89M | -25.15%61.25M | -18.39%69.23M | -16.68%75.98M | -12.17%89.4M |
| Other receivables (including interest and dividends) | -64.27%1.43M | -72.99%1.14M | -68.20%1.32M | 4.34%4.52M | -1.60%4.01M | 180.57%4.22M | 1.70%4.17M | -11.12%4.33M | 315.67%4.08M | -2.69%1.5M |
| -Other receivable | -64.27%1.43M | ---- | -68.20%1.32M | ---- | -1.60%4.01M | ---- | 1.70%4.17M | ---- | 315.67%4.08M | ---- |
| Advance payment | -97.56%130.46K | 10.03%5.07M | -23.51%3.44M | -97.53%115.25K | 41.08%5.35M | 297.62%4.61M | 211.54%4.5M | 74.70%4.66M | 275.34%3.79M | -70.01%1.16M |
| Inventories | -24.00%81.37M | -16.86%90.18M | -2.78%96.45M | 11.29%108.46M | 20.17%107.06M | 27.03%108.47M | -0.96%99.22M | -11.25%97.46M | -27.60%89.09M | -38.36%85.39M |
| Other current assets | -40.43%6.34M | -7.83%7.48M | 13.88%9.7M | -52.21%8.06M | -37.81%10.65M | 1,018.07%8.12M | 194.91%8.52M | 72.15%16.86M | 33.50%17.12M | -82.22%726.15K |
| Total current assets | 26.50%1.71B | 31.45%1.69B | 9.88%1.38B | 5.45%1.4B | 2.47%1.35B | -12.24%1.29B | -13.26%1.26B | -11.08%1.33B | -13.71%1.32B | -2.54%1.46B |
| Non Current assets | ||||||||||
| Other non-current financial assets | -60.20%251.48M | -65.62%256.03M | -30.63%545.82M | -14.06%482.98M | 10.91%631.81M | 29.98%744.74M | 39.07%786.82M | 23.05%561.97M | 46.00%569.67M | 138.28%572.96M |
| Long-term equity investment | -12.02%706.4M | -13.64%719.91M | -18.50%727.61M | -14.28%702.52M | -3.22%802.91M | 21.07%833.61M | 29.01%892.82M | 28.15%819.54M | 33.38%829.62M | 49.48%688.52M |
| Fixed assets | -8.42%476.95M | ---- | -7.22%499.01M | ---- | -6.91%520.79M | ---- | -7.86%537.86M | ---- | 5.99%559.46M | ---- |
| Constru in process | 953.18%11.03M | ---- | 183.87%1.37M | ---- | 219.82%1.05M | ---- | --482.24K | ---- | -99.54%327.52K | ---- |
| Productive biological assets | 26.64%7.01M | 20.10%6.86M | 2.45%5.95M | --6.15M | --5.53M | --5.71M | --5.81M | ---- | ---- | ---- |
| Intangible assets | -5.67%47.12M | -5.76%47.96M | -7.43%47.84M | -7.24%48.91M | -7.12%49.95M | -7.95%50.89M | -8.26%51.68M | -8.13%52.72M | -7.98%53.78M | 8.51%55.28M |
| Development expenditure | 40.07%292.71M | 29.29%261.17M | 27.47%247.95M | 12.33%209.4M | 13.53%208.97M | 14.16%202M | 17.64%194.51M | 15.69%186.42M | 16.12%184.07M | 16.31%176.95M |
| Goodwill | 0.00%21.87M | 0.00%21.87M | 0.00%21.87M | 0.00%21.87M | 0.00%21.87M | 0.00%21.87M | 0.00%21.87M | 0.00%21.87M | 0.00%21.87M | 0.00%21.87M |
| Long deferred expense | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Deferred tax assets | -26.24%1.79M | -55.69%2.34M | -56.24%2.35M | -44.81%2.52M | -54.52%2.42M | 108.12%5.27M | 112.89%5.38M | 76.75%4.57M | 111.61%5.33M | -8.73%2.53M |
| Usufruct assets | -2.91%11.69M | -2.35%11.85M | -2.33%11.93M | -2.85%11.96M | -2.83%12.04M | --12.13M | --12.22M | --12.31M | --12.4M | ---- |
| Other non current assets | 3.15%12.16M | -2.40%11.21M | -1.37%11.4M | 4.18%11.45M | -2.75%11.79M | -20.00%11.49M | 4.56%11.56M | -80.50%10.99M | -36.23%12.12M | 3.86%14.36M |
| Total non current assets | -18.90%1.84B | -24.42%1.83B | -15.78%2.12B | -9.50%2.01B | 0.91%2.27B | 14.85%2.42B | 20.12%2.52B | 11.99%2.22B | 20.15%2.25B | 36.15%2.11B |
| Total assets | -1.94%3.55B | -5.03%3.52B | -7.25%3.5B | -3.90%3.41B | 1.49%3.62B | 3.74%3.7B | 6.49%3.78B | 2.07%3.55B | 4.92%3.57B | 17.09%3.57B |
| Liabilities | ||||||||||
| Current liabilities | ||||||||||
| Notes payable and accounts payable | 3.92%15.72M | 10.30%11.49M | -2.73%11.11M | -23.32%16.37M | -29.97%15.13M | -59.61%10.42M | -56.78%11.42M | 26.01%21.35M | -21.21%21.61M | 14.92%25.79M |
| -Accounts payable | 3.92%15.72M | 10.30%11.49M | -2.73%11.11M | -23.32%16.37M | -29.97%15.13M | -59.61%10.42M | -56.78%11.42M | 26.01%21.35M | -21.21%21.61M | 14.92%25.79M |
| Contract liabilities | -18.57%4.95M | -0.86%6.42M | 0.94%5.64M | -40.14%5.12M | -30.65%6.08M | -23.17%6.48M | -45.43%5.59M | -26.21%8.56M | -28.67%8.77M | 10.64%8.43M |
| Advance receipts | 0.00%352.29K | ---- | ---- | ---- | 0.00%352.29K | ---- | ---- | ---- | 28.00%352.29K | --0 |
| Salaries payable | 10.85%5.27M | -14.18%4.54M | -17.25%4.55M | -14.60%4.92M | -8.65%4.76M | 16.31%5.29M | 23.42%5.5M | 19.19%5.76M | -14.08%5.21M | -2.90%4.55M |
| Taxs payable | 501.35%8.08M | 15.30%2.13M | -28.82%2.19M | -22.21%2.64M | -58.94%1.34M | -78.74%1.84M | -32.53%3.07M | -50.01%3.4M | -54.35%3.27M | -14.87%8.68M |
| Other payable (including interest and dividends) | 104.57%47.04M | 326.43%57.69M | 122.97%50.12M | 143.52%37.42M | -33.52%22.99M | -5.05%13.53M | 89.21%22.48M | 180.48%15.37M | 2.00%34.59M | -68.41%14.25M |
| -Other payable | 104.57%47.04M | ---- | 122.97%50.12M | ---- | -33.52%22.99M | ---- | 89.21%22.48M | ---- | 2.00%34.59M | ---- |
| Non current liabilities due within one year | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Other current liabilities | -19.13%639.43K | -0.86%835.17K | 0.94%733.21K | -40.14%665.87K | -30.65%790.65K | -23.17%842.46K | -45.43%726.36K | -26.21%1.11M | -14.26%1.14M | 10.64%1.1M |
| Total current liabilities | 59.49%82.05M | 116.41%83.11M | 52.38%74.33M | 20.88%67.14M | -31.34%51.45M | -38.84%38.4M | -17.15%48.78M | 17.79%55.54M | -15.29%74.94M | -31.02%62.8M |
| Current liabilities | ||||||||||
| Deferred tax liabilities | -19.37%83.18M | -20.44%80.25M | -25.05%80.37M | -16.46%67.81M | 25.56%103.16M | 96.50%100.87M | 108.21%107.22M | 99.68%81.16M | 173.12%82.16M | 613.50%51.33M |
| Long term deferred income | --1.24M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Total non current liabilities | -18.16%84.43M | -20.44%80.25M | -25.05%80.37M | -16.46%67.81M | 25.56%103.16M | 96.50%100.87M | 108.21%107.22M | 99.68%81.16M | 173.12%82.16M | 613.50%51.33M |
| Total liabilities | 7.68%166.48M | 17.30%163.36M | -0.83%154.7M | -1.29%134.94M | -1.58%154.61M | 22.03%139.27M | 41.34%156M | 55.70%136.7M | 32.52%157.1M | 16.18%114.13M |
| Shareholders equity | ||||||||||
| Paid-in capital | 0.00%481.67M | 0.00%481.67M | 0.00%481.67M | 0.00%481.67M | 0.00%481.67M | 0.00%481.67M | 0.00%481.67M | 0.00%481.67M | 0.00%481.67M | 0.00%481.67M |
| Capital reserve funds | 0.00%845.93M | 0.00%845.93M | 0.00%845.93M | 0.00%845.93M | 0.00%845.93M | 0.28%845.93M | 0.28%845.93M | 0.28%845.93M | 0.28%845.93M | 0.63%843.56M |
| Surplus reserve funds | 0.00%244.68M | 0.00%244.68M | 0.00%244.68M | 0.00%244.68M | 0.00%244.68M | 9.74%244.68M | 9.74%244.68M | 9.74%244.68M | 9.74%244.68M | 27.53%222.96M |
| Retained profit | -4.26%1.78B | -10.35%1.75B | -13.15%1.75B | -7.21%1.67B | 3.42%1.86B | 4.57%1.96B | 8.59%2.01B | -0.20%1.8B | 6.01%1.8B | 31.95%1.87B |
| Other composite income | 58.64%1.45M | -61.89%534.61K | -30.30%1.14M | 803.34%978.73K | 181.85%917.04K | 40.38%1.4M | 273.69%1.63M | 94.95%-139.16K | 112.43%325.37K | 148.30%999.33K |
| Shareholders equity without minority interests | -2.30%3.36B | -5.76%3.33B | -7.39%3.32B | -3.82%3.25B | 1.84%3.44B | 3.22%3.53B | 5.46%3.59B | 0.69%3.37B | 3.98%3.37B | 17.50%3.42B |
| Minority interests | -10.52%28.26M | -20.89%27.57M | -20.86%28.46M | -20.76%29.85M | -17.09%31.58M | -4.52%34.85M | -2.84%35.97M | 0.07%37.67M | -0.74%38.09M | -10.43%36.5M |
| Total shareholder equity | -2.37%3.39B | -5.91%3.35B | -7.52%3.35B | -4.00%3.28B | 1.63%3.47B | 3.13%3.56B | 5.37%3.62B | 0.68%3.41B | 3.93%3.41B | 17.12%3.46B |
| Total liabilityies and equity | -1.94%3.55B | -5.03%3.52B | -7.25%3.5B | -3.90%3.41B | 1.49%3.62B | 3.74%3.7B | 6.49%3.78B | 2.07%3.55B | 4.92%3.57B | 17.09%3.57B |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | Grant Thornton Certified Public Accountants (Special General Partnership) | -- | -- | -- | Grant Thornton Certified Public Accountants (Special General Partnership) | -- | -- | -- | Grant Thornton Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.